Parkinson's Disease: Symptoms, Mechanism, and Treatment — a Complete Overview

Parkinson's disease is the second most common neurodegenerative disease in the world after Alzheimer's, yet public awareness of it is usually limited to a single symptom — resting tremor of the hands. In reality, the clinical picture of the disease is far broader and includes both classic motor symptoms and a range of non-motor symptoms, some of which precede movement problems by even years, though they're rarely connected to Parkinson's in time.

At the root of the disease lies the progressive loss of dopaminergic neurons in the substantia nigra — a midbrain structure responsible for producing dopamine, a neurotransmitter crucial for smooth movement control. Motor symptoms typically appear only once 50-70% of the dopaminergic neurons in this region have already been lost — meaning the neurodegenerative process runs for many years before the disease becomes clinically apparent.

Under the current diagnostic criteria of the International Parkinson and Movement Disorder Society (MDS), a necessary condition for diagnosing parkinsonism is the presence of bradykinesia combined with at least one of the other three symptoms — tremor alone, without bradykinesia, is not sufficient to diagnose Parkinson's disease and may point to another cause of tremor.

Parkinson's disease is increasingly understood as a systemic disease, not solely a motor one. Non-motor symptoms, some of which can precede diagnosis by years, include: loss of smell (hyposmia), REM sleep behavior disorder (violently "acting out" dreams, sometimes injuring a partner or oneself), chronic constipation, depression and anxiety, cognitive impairment, excessive daytime sleepiness, and autonomic dysfunction — including drops in blood pressure on standing (orthostatic hypotension).

Dopamine produced in the substantia nigra is transported to the striatum, a structure responsible for coordinating and initiating smooth voluntary movements. Progressive loss of dopaminergic neurons disrupts this circuit, leading to the slowness, rigidity, and tremor characteristic of the disease. The exact cause of these neurons' death remains under investigation — likely contributors include abnormal accumulation of the protein alpha-synuclein (forming so-called Lewy bodies), mitochondrial dysfunction, oxidative stress, and — in a small percentage of patients — genetic factors, while in most cases the disease is sporadic, without a single, clear cause.

It's this dopamine deficit, not the neuron loss itself, that is the direct target of most currently available symptomatic treatment — medications don't stop the neurodegenerative process, but replace the missing dopamine or mimic its action, easing motor symptoms for as long as the number of remaining functional neurons allows a response to treatment.

Levodopa, a dopamine precursor capable of crossing the blood-brain barrier (unlike dopamine itself), has remained the most effective symptomatic drug in Parkinson's disease for over fifty years and the benchmark against which every new drug in this indication is compared. It's always given together with a peripheral decarboxylase inhibitor (carbidopa or benserazide), which limits its breakdown outside the brain and reduces side effects.

Besides levodopa, Parkinson's disease treatment includes dopamine receptor agonists (e.g., pramipexole, ropinirole), which directly stimulate dopamine receptors and carry a lower risk of dyskinesias but more often cause drowsiness, impulse control disorders, and edema; MAO-B inhibitors (e.g., rasagiline, selegiline), which slow the breakdown of dopamine in the brain; COMT inhibitors, which extend the effect of a single levodopa dose; and — in advanced cases resistant to pharmacological treatment — deep brain stimulation (DBS), a neurosurgical procedure involving the implantation of electrodes stimulating specific subcortical structures.

Beyond pharmacotherapy and surgical treatment, regular physical activity has documented significance in slowing the progression of motor symptoms and improving quality of life in Parkinson's disease — a topic broad and distinct enough that we've dedicated a separate, detailed article to it: physical activity and Parkinson's disease, which we recommend for more information on specific forms of exercise and the evidence for their effectiveness.

Parkinson's disease is chronic and progressive, but the pace of progression varies considerably between patients — in some, symptoms remain relatively mild for many years, while in others the disease progresses much faster. As the disease progresses, levodopa's effectiveness in controlling motor symptoms gradually diminishes, and non-motor symptoms — especially cognitive impairment and balance problems, which respond less to dopaminergic treatment than classic motor symptoms — become increasingly significant.

Parkinson's disease doesn't directly shorten life to the degree its severity might suggest — with well-managed treatment and care, many patients live with the disease for decades, though quality of life and the degree of functional independence depend significantly on the rate of progression, access to rehabilitation, and the effectiveness of controlling both motor and non-motor symptoms.

Parkinson's disease remains one where awareness of the broad symptom spectrum — not just hand tremor — genuinely affects time to diagnosis. Levodopa, after five decades of use, still has no equally effective successor for controlling motor symptoms, which itself shows how difficult a therapeutic target this disease remains — and why both pharmacotherapy and non-pharmacological interventions like regular exercise play complementary, not competing, roles in its management.